Definitions
The following definitions represent the CraNE CCCN lung cancer patient pathway according to the BPMN model. The definitions are created using the formerly introduced FHIR Profiles and Extensions.
Pathway Definitions
| Name | Title | Description |
|---|---|---|
| CraNE_CCCN_Pathway_Definition | CraNE CCCN Pathway Definition | CraNE Comprehensive Cancer Care Network Pathway Definition |
| CraNE_CCCN_Pathway_Process_Flow_Definition | CraNE CCCN Pathway Process Flow Definition | CraNE Comprehensive Cancer Care Network Pathway Process Flow Definition |
Pathway Activity Definitions
| Name | Title | Description |
|---|---|---|
| CraNE_CCCN_Pathway_Activity_Screening_Definition | Screening | CraNE Comprehensive Cancer Care Network Pathway Activity Screening Definition |
| CraNE_CCCN_Pathway_Activity_Patient_Consultation_Definition | Patient Consultation | CraNE Comprehensive Cancer Care Network Pathway Activity Patient Consultation Definition |
| CraNE_CCCN_Pathway_Activity_Staging_Diagnostics_Definition | Staging Diagnostics | CraNE Comprehensive Cancer Care Network Pathway Activity Staging Diagnostics Definition |
| CraNE_CCCN_Pathway_Activity_Treatment_Planning_Definition | Treatment Planning | CraNE Comprehensive Cancer Care Network Pathway Activity Treatment Planning Definition |
| CraNE_CCCN_Pathway_Activity_Treatment_Definition | Treatment | CraNE Comprehensive Cancer Care Network Pathway Activity Treatment Definition |
| CraNE_CCCN_Pathway_Activity_Follow-Up_Definition | Follow-Up | CraNE Comprehensive Cancer Care Network Pathway Activity Follow-Up Definition |
| CraNE_CCCN_Pathway_Activity_End-Of-Care_Definition | End of CCCN Care | CraNE Comprehensive Cancer Care Network Pathway Activity End-Of-Care Definition |
Report Quality Indicator Definitions
| Name | Title | Description |
|---|---|---|
| CraNE_CCCN_Report_QI_01 | Report Quality Indicator #01 | QI 1: Percentage of patients having surgery for a NSCLC discussed in a postoperative tumour board/MDT meeting |
| CraNE_CCCN_Report_QI_02 | Report Quality Indicator #02 | QI 2: Pretherapeutic tumour board/MDT meeting |
| CraNE_CCCN_Report_QI_03 | Report Quality Indicator #03 | QI 3: PD-L1 testing for NSCLC in stage III with radiochemotherapy |
| CraNE_CCCN_Report_QI_04 | Report Quality Indicator #04 | QI 4: Pathological Diagnosis |
| CraNE_CCCN_Report_QI_05 | Report Quality Indicator #05 | QI 5: Pathological Diagnosis – tumour subtype |
| CraNE_CCCN_Report_QI_06 | Report Quality Indicator #06 | QI 6: Pre-treatment diagnosis |
| CraNE_CCCN_Report_QI_07 | Report Quality Indicator #07 | QI 7: Surgical expertise: Number of lung resections |
| CraNE_CCCN_Report_QI_08 | Report Quality Indicator #08 | QI 8: Videothoracoscopic (VATS) and robotic-assisted (RATS) anatomical resections |
| CraNE_CCCN_Report_QI_09 | Report Quality Indicator #09 | QI 9: Local R0 resections in stages IA/B and IIA/B |
| CraNE_CCCN_Report_QI_10 | Report Quality Indicator #10 | QI 10: Local R0 resections in stages IIIA/B |
| CraNE_CCCN_Report_QI_11 | Report Quality Indicator #11 | QI 11: Anatomical pulmonary resection for NSCLC stage I/II with a tumour >= 2cm |
| CraNE_CCCN_Report_QI_12 | Report Quality Indicator #12 | QI 12: Surgical Lymph Node Staging >=10 Lymph nodes at resection |
| CraNE_CCCN_Report_QI_13 | Report Quality Indicator #13 | QI 13: Stage II-III NSCLC patients receiving chemo-radiation |
| CraNE_CCCN_Report_QI_14 | Report Quality Indicator #14 | QI 14: Adjuvant cisplatin-based chemotherapy for stages II-IIIA1/2 |
| CraNE_CCCN_Report_QI_15 | Report Quality Indicator #15 | QI 15: Stereotactic Ablative Radiotherapy (SABR) in inoperable stage I Lung Cancer |
| CraNE_CCCN_Report_QI_16 | Report Quality Indicator #16 | QI 16: Interventional Bronchoscopy (Thermal Procedures and Stenting) |
| CraNE_CCCN_Report_QI_17 | Report Quality Indicator #17 | QI 17: Chemo-immunotherapy in SCLC |
| CraNE_CCCN_Report_QI_18 | Report Quality Indicator #18 | QI 18: Clinical Trials and Research Study Access |
| CraNE_CCCN_Report_QI_19 | Report Quality Indicator #19 | QI 19: Post-operative bronchial stump/anastomotic insufficiency |
| CraNE_CCCN_Report_QI_20 | Report Quality Indicator #20 | QI 20: Maintenance therapy after definitive radiochemotherapy |
Quality Indicator Definitions
| Name | Title | Description |
|---|---|---|
| CraNE_CCCN_QI_01 | Quality Indicator #01 | QI 1: Percentage of patients having surgery for a NSCLC discussed in a postoperative tumour board/MDT meeting |
| CraNE_CCCN_QI_02 | Quality Indicator #02 | QI 2: Pretherapeutic tumour board/MDT meeting |
| CraNE_CCCN_QI_03 | Quality Indicator #03 | QI 3: PD-L1 testing for NSCLC in stage III with radiochemotherapy |
| CraNE_CCCN_QI_04 | Quality Indicator #04 | QI 4: Pathological Diagnosis |
| CraNE_CCCN_QI_05 | Quality Indicator #05 | QI 5: Pathological Diagnosis – tumour subtype |
| CraNE_CCCN_QI_06 | Quality Indicator #06 | QI 6: Pre-treatment diagnosis |
| CraNE_CCCN_QI_07 | Quality Indicator #07 | QI 7: Surgical expertise: Number of lung resections |
| CraNE_CCCN_QI_08 | Quality Indicator #08 | QI 8: Videothoracoscopic (VATS) and robotic-assisted (RATS) anatomical resections |
| CraNE_CCCN_QI_09 | Quality Indicator #09 | QI 9: Local R0 resections in stages IA/B and IIA/B |
| CraNE_CCCN_QI_10 | Quality Indicator #10 | QI 10: Local R0 resections in stages IIIA/B |
| CraNE_CCCN_QI_11 | Quality Indicator #11 | QI 11: Anatomical pulmonary resection for NSCLC stage I/II with a tumour >= 2cm |
| CraNE_CCCN_QI_12 | Quality Indicator #12 | QI 12: Surgical Lymph Node Staging >=10 Lymph nodes at resection |
| CraNE_CCCN_QI_13 | Quality Indicator #13 | QI 13: Stage II-III NSCLC patients receiving chemo-radiation |
| CraNE_CCCN_QI_14 | Quality Indicator #14 | QI 14: Adjuvant cisplatin-based chemotherapy for stages II-IIIA1/2 |
| CraNE_CCCN_QI_15 | Quality Indicator #15 | QI 15: Stereotactic Ablative Radiotherapy (SABR) in inoperable stage I Lung Cancer |
| CraNE_CCCN_QI_16 | Quality Indicator #16 | QI 16: Interventional Bronchoscopy (Thermal Procedures and Stenting) |
| CraNE_CCCN_QI_17 | Quality Indicator #17 | QI 17: Chemo-immunotherapy in SCLC |
| CraNE_CCCN_QI_18 | Quality Indicator #18 | QI 18: Clinical Trials and Research Study Access |
| CraNE_CCCN_QI_19 | Quality Indicator #19 | QI 19: Post-operative bronchial stump/anastomotic insufficiency |
| CraNE_CCCN_QI_20 | Quality Indicator #20 | QI 20: Maintenance therapy after definitive radiochemotherapy |